Creative Medical Technology Holdings Inc (CELZ) Actualités

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

PHOENIX, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a...

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

PHOENIX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form DEF 14A - Other definitive proxy statements

Form PRER14A - Preliminary Proxy Soliciting materials

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

PHOENIX, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical...

Form EFFECT - Notice of Effectiveness

Form PRE 14A - Other preliminary proxy statements

Form S-3 - Registration statement under Securities Act of 1933